Trulicity Compounding Legal Status: What Patients and Prescribers Need to Know

What Is Trulicity and How Did the FDA Approve It?

Trulicity (dulaglutide) is a once-weekly subcutaneous GLP-1 receptor agonist manufactured by Eli Lilly. The FDA granted approval on September 18, 2014, under New Drug Application 125469, initially for glycemic control in adults with type 2 diabetes at doses of 0.75 mg and 1.5 mg per week. The agency later approved higher doses of 3 mg and 4.5 mg following additional efficacy data.

The Approval Pathway

The FDA reviewed dulaglutide through its standard NDA process, requiring Eli Lilly to submit data from the AWARD (Assessment of Weekly AdministRation of dulaglutide) clinical trial program. That program included eight phase 3 trials spanning more than 5,000 patients across different comparators including metformin, sitagliptin, exenatide, insulin glargine, and placebo. [1]

The prescribing information approved at launch required a boxed warning for thyroid C-cell tumors based on rodent carcinogenicity data, a finding shared across the GLP-1 receptor agonist class. The FDA's full prescribing information for Trulicity is publicly available through Drugs@FDA and is the controlling legal document for all approved indications. [2]

Expanded Cardiovascular Indication

In 2020, the FDA approved an additional indication: reducing the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors. This approval rested on the REWIND trial, published in The Lancet in 2019. [3]

REWIND enrolled 9,901 participants across 24 countries and followed them for a median of 5.4 years. Dulaglutide 1.5 mg weekly reduced the composite MACE endpoint (nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death) by 12% relative to placebo (HR 0.88, 95% CI 0.79 to 0.99, P=0.026). [3] That trial remains one of the largest and longest GLP-1 cardiovascular outcomes studies conducted.

What the Trulicity Label Actually Says

The current FDA-approved label for Trulicity specifies six distinct areas prescribers must understand before initiating therapy.

Approved Indications

The label lists two approved uses: (1) adjunct to diet and exercise for glycemic control in adults with type 2 diabetes mellitus, and (2) reduction of major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors. [2] The label does not include weight loss as a standalone indication. Prescribers using it off-label for weight management alone should document that decision carefully.

Boxed Warning and Contraindications

The boxed warning states: "Dulaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice." The label formally contraindicates use in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2. [2]

Additional contraindications include known serious hypersensitivity reactions to dulaglutide or any product components. Prescribers must review the full label before initiating therapy given the class-specific risk profile. [4]

Dosing and Administration Requirements

The label specifies subcutaneous injection into the abdomen, thigh, or upper arm once weekly on the same day each week. Starting dose is 0.75 mg weekly for four weeks, then titration to 1.5 mg weekly. Further titration to 3 mg and then 4.5 mg is permitted based on glycemic response, with each dose increase occurring after at least four weeks at the prior dose. [2]

The product comes in a single-dose autoinjector pen. Unlike semaglutide, which is also available orally (Rybelsus), dulaglutide has no FDA-approved oral formulation. This matters because any oral or reconstituted injectable "dulaglutide" product from a compounding pharmacy would be a fundamentally different drug product from what the FDA approved.

Why Compounding Dulaglutide Is Now Illegal

This is the section most patients and prescribers get wrong. Compounding law in the United States does not prohibit all compounding. It prohibits compounding copies of commercially available drugs that are not on the FDA shortage list.

The Statutory Framework

Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act) govern compounding pharmacies. Section 503A covers traditional pharmacies compounding for individual patients with a valid prescription. Section 503B covers outsourcing facilities that compound without patient-specific prescriptions, typically for hospital or clinic use. [5]

Both sections share a critical restriction: compounding pharmacies may not compound a drug that is "essentially a copy" of a commercially available drug unless that drug appears on the FDA's current drug shortage list. The FDA published this framework in guidance documents covering 503A and 503B separately. [6]

The Shortage Period and Its End

During 2022 and into 2023, Trulicity experienced documented supply disruptions. The FDA placed dulaglutide on its official drug shortage database during this period, which temporarily allowed 503A and 503B pharmacies to compound preparations containing dulaglutide. Prescribers and patients who obtained compounded dulaglutide during that specific window were operating within the law at the time.

The FDA removed dulaglutide from the shortage list in 2023. That removal triggered an automatic prohibition on further compounding of essentially-copy dulaglutide products. There is no grace period written into the statute for 503A pharmacies after a drug exits shortage status. [5]

What "Essentially a Copy" Means

The FDA defines "essentially a copy" as a drug product that has the same active pharmaceutical ingredient (API), route of administration, and dosage form as the commercially available product. A compounded vial of dulaglutide for subcutaneous injection fits this definition precisely. Adding a flavoring agent or changing the concentration does not remove a product from this category under current agency guidance. [6]

Some compounding pharmacies have attempted to market "dulaglutide peptide fragments" or structurally modified analogs. These products carry additional legal risk: they are not dulaglutide, they are not FDA-approved, and they may be subject to enforcement as unapproved new drugs entirely separate from the shortage-based compounding prohibition. [7]

HealthRX Prescriber Decision Framework: Dulaglutide Compounding Eligibility Check

Before writing any prescription that involves compounded dulaglutide, apply this three-question test:

1. Is dulaglutide currently listed on the FDA drug shortage database at accessdata.fda.gov? If no, compounding is not permitted under 503A or 503B. Stop here.
2. Is the compounding pharmacy registered as a 503B outsourcing facility, or is it a licensed 503A pharmacy receiving a patient-specific prescription? Both require an active shortage listing, but 503B has additional bulk compounding restrictions.
3. Does the product being compounded share the same API, route, and dosage form as FDA-approved Trulicity? If yes, it is "essentially a copy" and cannot be compounded absent a shortage listing.

If the answer to question 1 is no, the other questions are moot. As of the date of this article, dulaglutide is not on the FDA shortage list.

FDA Post-Market Surveillance and Safety Data

FDA approval does not end regulatory oversight. The agency tracks post-market safety through several mechanisms that apply to Trulicity.

FAERS Reporting

The FDA Adverse Event Reporting System (FAERS) collects voluntary reports from patients, healthcare providers, and manufacturers after a drug reaches market. For GLP-1 receptor agonists as a class, FAERS data have contributed to label updates on pancreatitis risk, acute kidney injury, and hypersensitivity reactions. [8]

Eli Lilly is required under post-market safety reporting obligations to submit periodic safety update reports (PSURs) to the FDA and equivalent dossiers to international regulators including the European Medicines Agency. The EMA's European Public Assessment Report (EPAR) for dulaglutide is publicly searchable and provides an independent regulatory perspective on the benefit-risk profile of Trulicity as assessed outside the United States. [9]

Pancreatitis and Pancreatic Cancer Signal

The Trulicity label carries a warning about pancreatitis. In preapproval trials, acute pancreatitis was reported in 13 of approximately 4,006 dulaglutide-treated patients versus 1 of 1,677 comparator patients. [2] Prescribers should discontinue dulaglutide and not restart it if pancreatitis is confirmed.

Post-market observational data have not established a causal link between GLP-1 receptor agonists and pancreatic cancer. A 2014 JAMA Internal Medicine meta-analysis and subsequent analyses have not found a statistically significant increase in pancreatic cancer risk with GLP-1 agonist use. [10] The FDA continues to monitor this signal through FAERS and Sentinel network analyses.

Sentinel System Monitoring

The FDA's Sentinel System uses claims and electronic health record data from over 100 million patients to conduct active surveillance on approved drugs. Dulaglutide is included in ongoing Sentinel analyses covering GLP-1 receptor agonist class effects. The Sentinel System represents a significant advance in pharmacovigilance compared to passive FAERS reporting alone. [11]

Renal and Cardiac Safety Signals

The REWIND trial reported that dulaglutide reduced the composite renal outcome of new macroalbuminuria, sustained decline in eGFR of 30% or more, or chronic renal replacement therapy by 15% compared with placebo (HR 0.85, 95% CI 0.77 to 0.93). [3] This renal benefit signal has influenced clinical practice guidelines from the American Diabetes Association, which now include GLP-1 receptor agonists as preferred agents in patients with diabetic kidney disease. [12]

How Trulicity Compares to Other GLP-1 Agents Under Compounding Rules

GLP-1 receptor agonist compounding has been one of the most active regulatory areas in telehealth and weight management over the past three years. Understanding where dulaglutide sits relative to semaglutide and tirzepatide helps prescribers avoid unintentional legal exposure.

Semaglutide Shortage History

Semaglutide (Ozempic and Wegovy) remained on the FDA drug shortage list significantly longer than dulaglutide, allowing compounding pharmacies to legally compound semaglutide-containing products through most of 2023 and into 2025. The FDA declared the Wegovy (semaglutide 2.4 mg) shortage resolved in early 2025 and set a compliance timeline for 503B outsourcing facilities and 503A pharmacies to cease compounding. [13]

That resolution does not affect dulaglutide. Dulaglutide exited shortage status earlier and has been off the shortage list longer.

Tirzepatide Status

Tirzepatide (Mounjaro and Zepbound) had an active shortage listing that also concluded in 2025. The FDA has issued enforcement discretion guidance for tirzepatide compounding, with phased wind-down timelines. [13] Again, these tirzepatide-specific timelines are separate from and do not affect dulaglutide.

What Prescribers Should Document

Any prescriber operating a telehealth practice that previously offered compounded GLP-1 agents should confirm through the FDA shortage database that each specific active ingredient remains listed before writing or renewing prescriptions. Relying on a pharmacy's assurances rather than checking the official FDA shortage database directly is not a defensible clinical or legal practice. [5]

Clinical Transition: What to Do When a Patient Is on Compounded Dulaglutide

Patients who received compounded dulaglutide during the shortage period need a clear clinical transition plan now that the shortage has ended.

Assessing Current Glycemic Control

Before switching, obtain a current HbA1c and fasting glucose. Patients who achieved glycemic targets on compounded dulaglutide may be stable enough for a direct switch to FDA-approved Trulicity at the equivalent weekly dose. The pharmacokinetic and pharmacodynamic profile of properly compounded dulaglutide should mirror the approved product, though batch-to-batch variability in compounded preparations is a documented concern. [7]

Switching Protocol

The FDA-approved Trulicity autoinjector delivers 0.75 mg or 1.5 mg per weekly injection in a fixed-dose device. Patients accustomed to dose-flexible compounded preparations may need counseling that the commercial product comes in preset doses. Titration from 0.75 mg to 1.5 mg requires four weeks at the starting dose. For patients who were on higher doses (equivalent to 3 mg or 4.5 mg) during the compounding period, the 3 mg and 4.5 mg Trulicity doses are FDA-approved and commercially available. [2]

Insurance and Prior Authorization

Commercial insurance coverage for Trulicity varies. As of 2024, GoodRx data indicate retail cash prices for Trulicity range from approximately $800 to $950 per month for the 1.5 mg weekly dose before manufacturer coupons. Eli Lilly's Trulicity savings card program may reduce out-of-pocket costs for commercially insured patients to as low as $25 per month, subject to eligibility requirements. Prescribers should proactively address insurance barriers to prevent patients from seeking illegal compounded alternatives due to cost. [14]

Regulatory Enforcement Risk for Prescribers and Pharmacies

The FDA has moved from warning letters to more aggressive enforcement on unapproved compounded GLP-1 products. Prescribers should understand the risk field clearly.

Warning Letters and Seizures

Between 2023 and 2025, the FDA issued multiple warning letters to compounding pharmacies distributing compounded semaglutide and tirzepatide products. Several pharmacies received letters specifically citing 503B violations for compounding drugs not on the shortage list. The FDA has statutory authority under 21 U.S.C. 331 to pursue injunctions, seizures, and criminal prosecution for interstate distribution of adulterated or misbranded drugs. [15]

Compounded dulaglutide distributed after the shortage ended meets the statutory definition of an unapproved new drug if it is distributed across state lines, exposing distributing pharmacies to this enforcement framework.

Prescriber Liability

Prescribers who write prescriptions for compounded drugs that are not legally permissible under 503A or 503B may face scrutiny from state medical boards in addition to federal DEA and FDA enforcement. While the FDA does not typically pursue individual prescribers for writing prescriptions (enforcement focuses on compounders and distributors), state boards in California, Texas, and Florida have each taken action against prescribers who participated in large-scale unapproved compounding schemes. [16]

Writing a prescription for a compounded drug does not transfer legal responsibility entirely to the pharmacy. Prescribers should verify shortage status independently.